期刊文献+

安全有效的HIV治疗与预防性疫苗的设计、开发和成功应用 被引量:1

Design, Development and Successful Application of Safe and Effective HIV Therapeutic and Prophylactic Vaccines
下载PDF
导出
摘要 普遍认为引起肆虐全球的HIV/AIDS大流行的病原体HIV是不可治愈并且是致命的。自从 20多年前发现并分离出病毒后,全世界在生产预防性和治疗性疫苗的努力至今都是失败的。作者在尼日利亚设计开发了HIV疫苗,并且已经应用这些疫苗分别对知情同意的HIV感染者和正常人进行了试验。在许多病例中,治疗性疫苗不仅在HIV感染的症状上产生了快速的改善,而且许多患者持续的抗 HIV抗体血清转阴。在那些并发HBV和 /或HCV感染的HIV患者中,治疗性疫苗产生了持续的抗HBsAg和抗HCV抗体转阴。使用这些疫苗至今没有观察到显著的不良反应,也没有引起可检测的标志性抗 HIV抗体产生。推测这种疫苗可诱导针对HIV、HBV和HCV感染细胞有效的选择性的细胞介导的细胞毒性免疫应答。 It is generally held that HIV, the causative agent of the rampaging global HIV/AIDS pandemic, is incurable and uniformly fatal. Since the discovery and isolation of the virus over two decades ago, global efforts at producing preventive and curative vaccines against it have so far resulted in failure. Working single-handedly with only his family's meagre resources and against the tide of universally accepted dogmas on HIV/AIDS, the author designed, developed and applied new HIV therapeutic and preventive vaccines in Nigeria, and has been using them on willing HIV-infected and normal persons respectively with their informed and written consent since their development. In many cases, the therapeutic vaccine produced rapid improvement not only in the symptoms and signs attributable to HIV infection, but also in various laboratory parameters with a sustained serodeconversion to HIV antibody negative status in a number of the patients. In those HIV-infected patients with concomitant hepatitis B (HBV) and/or C (HCV) infection(s), the therapeutic vaccine has resulted in maintained serodeconversion to negative (normal) for the HBsAg and HCV antibodies also. No significant adverse or side effect has been observed yet with the use of these vaccines. The vaccines do not cause the production of any detectable levels of stigmatizing anti-HIV antibodies. It is postulated that the vaccines elicit effective but selective cell-mediated cytotoxic immune responses against HIV, HBV and HCV-infected cells.
出处 《中华男科学杂志》 CAS CSCD 2005年第1期8-16,共9页 National Journal of Andrology
关键词 HIV疫苗 治疗 预防 安全性 有效性 AIDS HIV感染 抗HIV抗体 血清抗体转阴 HBV HCV 细胞介导 细胞毒性 免疫应答 HIV vaccine therapy prevention safety efficacy AIDS HIV infection anti-HIV antibody serodeconversion HBV HCV cell-mediated cytotoxic immune response
  • 相关文献

参考文献1

二级参考文献34

  • 1Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [ see comments] [J]. Nature, 1995, 373(6510):123-126.
  • 2Smith K. Optimal clinical trial designs for immune-based therapies in persistent viral infections [J]. Med Immunol, 2002, 1(1):4.
  • 3Montagnier L. Historical essay. A history of HIV discovery [J].Science, 2002, 298 (5599): 1727-1728.
  • 4Gallo R. Historical essay. The early years of HIV/AIDS [J].Science, 2002, 298(5599) :1728-1730.
  • 5Smith K. Medical immunology: a new journal for a new subspecialty [ J]. Med I mmunol, 2002, 1 ( 1 ): 1.
  • 6Jenner E. An inquiry into the causes and effects of variolae vaccinae, a disease discovered in some western counties of England [M]. London: Sampson Low. 1798.
  • 7Kwong P, Doyle M, Casper D, et al. HIV-1 evades antibodymediated neutralization through conformational masking of receptor-binding sites [J]. Nature, 2002, 420(6916) :678-682.
  • 8Ketas T, Frank I, Klasse P,et al. Human immunodeficiency virus type 1 attachment, coreceptor, and fusion inhibitors are active against both direct and trans infection of primary cells [ J]. J Virol, 2003, 77(4):2762-2767.
  • 9Yang X, Farzan M, Wyatt R, et al. Characterization of stable,soluble trimers containing complete ectodomains of human immunodeficiency virus type 1 envelope glycoproteins [ J ]. J Virol,2000, 74(12) :5716-5725.
  • 10Barre-Sinoussi F, Chermann J, Rey F, et al. Isolation of a Tlymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS) [ J]. Science, 1983, 220(4599):868 -871.

同被引文献3

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部